75%Confidence
0Views
FDASource
2026-04-01Date
Summary
Defective blister packaging for Midodrine tablets creates patient safety risks and suggests packaging process failures at Major Pharmaceuticals. This could result in product shortages and increased regulatory attention for cardiovascular medications.
Actionable: Verify packaging integrity for all blister-packed medications from affected facilities and review quality assurance protocols.
AI Confidence: 75%
Data Points
firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now